Variable coding sequence protein A1 as a marker for erectile dysfunction

Authors

  • YUEHONG TONG,

    1. Department of Urology, Albert Einstein College of Medicine, Bronx, New York, and Wake Forest University, Institute for Regenerative Medicine, Winston-Salem, NC, USA
    Search for more papers by this author
  • MOSES TAR,

    1. Department of Urology, Albert Einstein College of Medicine, Bronx, New York, and Wake Forest University, Institute for Regenerative Medicine, Winston-Salem, NC, USA
    Search for more papers by this author
  • FELIX DAVELMAN,

    1. Department of Urology, Albert Einstein College of Medicine, Bronx, New York, and Wake Forest University, Institute for Regenerative Medicine, Winston-Salem, NC, USA
    Search for more papers by this author
  • GEORGE CHRIST,

    1. Department of Urology, Albert Einstein College of Medicine, Bronx, New York, and Wake Forest University, Institute for Regenerative Medicine, Winston-Salem, NC, USA
    Search for more papers by this author
  • ARNOLD MELMAN,

    1. Department of Urology, Albert Einstein College of Medicine, Bronx, New York, and Wake Forest University, Institute for Regenerative Medicine, Winston-Salem, NC, USA
    Search for more papers by this author
  • KELVIN P. DAVIES

    1. Department of Urology, Albert Einstein College of Medicine, Bronx, New York, and Wake Forest University, Institute for Regenerative Medicine, Winston-Salem, NC, USA
    Search for more papers by this author

Kelvin P. Davies, Department of Urology, Albert Einstein College of Medicine, Room 744, Forchheimer Building, 1300 Morris Park Avenue, Bronx, NY 10461, USA. e-mail: kdavies@aecom.yu.edu

Abstract

OBJECTIVE

To investigate whether variable coding sequence protein A1 (Vcsa1) is down-regulated in rat models of diabetes and ageing, and to investigate the role of Vcsa1 in erectile function, as Vcsa1 is the most down-regulated gene in the corpora of a rat model of neurogenic erectile dysfunction (ED).

MATERIALS AND METHODS

Quantitative reverse-transcriptase polymerase-chain reaction was used to determine Vcsa1 expression in the corpora of rats in three models of ED, i.e. streptozotocin-induced diabetes, retired breeder (old), and neurogenic (bilaterally ligated cavernosal nerves), and in control rats. To confirm a physiological role of Vcsa1 in erectile function, we carried out gene transfer studies using a plasmid in which Vcsa1 was expressed from a cytomegalovirus promoter (pVAX-Vcsa1). This plasmid was injected intracorporally into old rats, and the effect on physiology of corporal tissue was analysed by intracorporal/blood pressure (ICP/BP) measurement and histological analysis, and compared with the effects of a positive control plasmid (pVAX-hSlo, which we previously reported to restore erectile function in diabetic and ageing rats) and a negative control plasmid (pVAX).

RESULTS

In each rat model of ED there was a significant down-regulation of the Vcsa1 transcript of at least 10-fold in corporal tissue. Remarkably, intracorporal injection with 80 µg pVAX-Vcsa1 caused priapism, as indicated by visible prolonged erection, histological appearance, and elevated resting ICP/BP. Lower doses of pVAX-Vcsa1 (5 and 25 µg) increased ICP/BP over that in untreated controls.

CONCLUSION

These results show that Vcsa1 has a role in erectile function and might be a molecular marker for organic ED. The role of Vcsa1 in erectile function suggests that it could represent a novel therapeutic target for treating ED.

Ancillary